PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the plasminogen (PLG) gene, as well as methods of inhibiting expression of PLG, and methods of treating subjects that would benefit from reduction in expression of PLG, such as subjects having a PLG-associated disease, disorder, or condition, using such dsRNA compositions.
1 . A double stranded ribonucleic acid (dsRNA) agent, or salt thereof, for inhibiting expression of plasminogen (PLG) in a cell,
wherein said dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region,
wherein the nucleotide sequence of the sense strand differs by no more than 4 bases from the nucleotide sequence of 5′-usgscaauCfgCfUfAfugaguuucua-3′ (SEQ ID. NO: 881) and the nucleotide sequence of the antisense strand differs by no more than 4 bases from the nucleotide sequence of 5′-usAfsgaaAfcucauagCfgAfuugcascsa-3′ (SEQ ID. NO: 1257),
wherein a, c, g, and u are 2′-O-methyl (2′-OMe) A, C, G, and U, respectively Af, Cf, Gf and Uf are 2′-fluoro A, C, G and U, respectively; s is a phosphorothioate linkage, and
wherein at least one strand is conjugated to a ligand.
2 - 71 . (canceled)
72 . The dsRNA agent, or salt thereof, of claim 1 , wherein the nucleotide sequence of the sense strand differs by no more than 3 bases from the nucleotide sequence of 5′-usgscaauCfgCfUfAfugaguuucua-3′ (SEQ ID NO: 881) and the nucleotide sequence of the antisense strand differs by no more than 3 bases from the nucleotide sequence of 5′-usAfsgaaAfcucauagCfgAfuugcascsa-3′ (SEQ ID NO: 1257).
73 . The dsRNA agent, or salt thereof, of claim 1 , wherein the nucleotide sequence of the sense strand differs by no more than 2 bases from the nucleotide sequence of 5′-usgscaauCfgCfUfAfugaguuucua-3′ (SEQ ID NO: 881) and the nucleotide sequence of the antisense strand differs by no more than 2 bases from the nucleotide sequence of 5′-usAfsgaaAfcucauagCfgAfuugcascsa-3′ (SEQ ID NO: 1257).
74 . The dsRNA agent, or salt thereof, of claim 1 , wherein the nucleotide sequence of the sense strand differs by no more than 1 base from the nucleotide sequence of 5′-usgscaauCfgCfUfAfugaguuucua-3′ (SEQ ID NO: 881) and the nucleotide sequence of the antisense strand differs by no more than 1 base from the nucleotide sequence of 5′-usAfsgaaAfcucauagCfgAfuugcascsa-3′ (SEQ ID NO: 1257).
75 . The dsRNA agent, or salt thereof, of claim 1 , wherein the ligand is conjugated to the 3′ end of the sense strand of the dsRNA agent.
76 . The dsRNA agent, or salt thereof, of claim 1 , wherein the ligand is an N-acetylgalactosamine (GalNAc) derivative.
77 . The dsRNA agent, or salt thereof, of claim 1 , wherein the ligand is one or more GalNAc derivatives attached through a monovalent, bivalent, or trivalent branched linker.
78 . The dsRNA agent, or salt thereof, of claim 77 , wherein the ligand is
79 . The dsRNA agent, or salt thereof, of claim 78 , wherein the dsRNA agent is conjugated to the ligand as shown in the following schematic
and, wherein X is O or S.
80 . The dsRNA agent, or salt thereof, of claim 79 , wherein the X is O.
81 . A double stranded ribonucleic acid (dsRNA) agent, or salt thereof, for inhibiting expression of plasminogen (PLG) in a cell,
wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region,
wherein the sense strand comprises the nucleotide sequence of 5′-usgscaauCfgCfUfAfugaguuucua-3′ (SEQ ID NO: 881) and the antisense strand comprises the nucleotide sequence of 5′-usAfsgaaAfcucauagCfgAfuugcascsa-3′ (SEQ ID NO: 1257),
wherein a, c, g, and u are 2′-O-methyl (2′-OMe) A, C, G, and U, respectively; Af, Cf, Gf and Uf are 2′-fluoro A, C, G and U, respectively; s is a phosphorothioate linkage, and
wherein at least one strand is conjugated to a ligand.
82 . The dsRNA agent, or salt thereof, of claim 81 , wherein the sense strand consists of the nucleotide sequence of 5′-usgscaauCfgCfUfAfugaguuucua-3′ (SEQ ID NO: 881) and the antisense strand consists of the nucleotide sequence of 5′-usAfsgaaAfcucauagCfgAfuugcascsa-3′ (SEQ ID NO: 1257).
83 . The dsRNA agent, or salt thereof, of claim 81 , wherein the ligand is conjugated to the 3′ end of the sense strand of the dsRNA agent.
84 . The dsRNA agent, or salt thereof, of claim 81 , wherein the ligand is an N-acetylgalactosamine (GalNAc) derivative.
85 . The dsRNA agent, or salt thereof, of claim 81 , wherein the ligand is one or more GalNAc derivatives attached through a monovalent, bivalent, or trivalent branched linker.
86 . The dsRNA agent, or salt thereof, of claim 85 , wherein the ligand is
87 . The dsRNA agent, or salt thereof, of claim 86 , wherein the dsRNA agent is conjugated to the ligand as shown in the following schematic
and, wherein X is O or S.
88 . The dsRNA agent, or salt thereof, of claim 87 , wherein the X is O.
89 . A double stranded ribonucleic acid (dsRNA) agent, or salt thereof, for inhibiting expression of plasminogen (PLG) in a cell,
wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region,
wherein the sense strand comprises the nucleotide sequence of 5′-usgscaauCfgCfUfAfugaguuucua-3′ (SEQ ID NO: 881) and the antisense strand comprises the nucleotide sequence of 5′-usAfsgaaAfcucauagCfgAfuugcascsa-3′ (SEQ ID NO: 1257),
wherein a, c, g, and u are 2′-O-methyl (2′-OMe) A, C, G, and U, respectively; Af, Cf, Gf and Uf are 2′-fluoro A, C, G and U, respectively; s is a phosphorothioate linkage, and
wherein the dsRNA agent is conjugated to a ligand as shown in the following schematic
90 . The dsRNA agent, or salt thereof, of claim 89 , wherein the sense strand consists of the nucleotide sequence of 5′-usgscaauCfgCfUfAfugaguuucua-3′ (SEQ ID NO: 881) and the antisense strand consists of the nucleotide sequence of 5′-usAfsgaaAfcucauagCfgAfuugcascsa-3′ (SEQ ID NO: 1257).
91 . A cell containing the dsRNA agent, or salt thereof, of claim 1 .
92 . A pharmaceutical composition for inhibiting expression of a gene encoding plasminogen (PLG) comprising the dsRNA agent, or salt thereof, of claim 1 and a pharmaceutically acceptable carrier.
93 . The pharmaceutical composition of claim 92 , wherein dsRNA agent, or salt thereof, is in an unbuffered solution.
94 . The pharmaceutical composition of claim 93 , wherein the unbuffered solution is saline or water.
95 . The pharmaceutical composition of claim 92 , wherein the dsRNA agent, or salt thereof, is in a buffer solution.
96 . The pharmaceutical composition of claim 95 , wherein the buffer solution comprises acetate, citrate, prolamine, carbonate, or phosphate, or any combination thereof.
97 . The pharmaceutical composition of claim 95 , wherein the buffer solution is phosphate buffered saline (PBS).
98 . The pharmaceutical composition of claim 92 , wherein the dsRNA agent is in a salt form.
99 . The pharmaceutical composition of claim 92 , wherein the dsRNA agent is in a sodium salt form.
100 . The pharmaceutical composition of claim 92 , wherein the dsRNA agent is in a free acid form.